Italian active pharmaceutical ingredients specialist Olon has announced “a further significant expansion of its generic pipeline” with the addition of two kinase inhibitor “NIBs”: pralsetinib tablets and injectable trilaciclib.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?